Prescient Therapeutics (ASX: PTX)
Live Investor Briefing
Register for an Upcoming Event
Please join us for a special investor briefing with Prescient Therapeutics CEO and MD Steven Yatomi-Clarke and Professor H. Miles Prince, specialist haematologist and principal investigator of the PTX-100 study.
In the session, Steven and Professor Prince will discuss:
- The results of the PTX-100 phase 1b trial, which exhibited excellent safety profile with no serious adverse events
- How the trial demonstrated a clinical signal seen in T cell lymphoma (TCL) patients
- PTX-100 will now progress to an expansion cohort study focussing on TCL with potential for subsequent registration study
This is a live and interactive online session, and participants are encouraged to ask questions. Joining only requires an internet connection. Spots are limited, so secure yours today.